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Introduction: Aortic stenosis is the most common structural heart disease. After symptom onset, 
the prognosis is very poor – over 50% of patients die within 2 years – unless they undergo aortic 
valve replacement. Transcatheter aortic valve replacement (TAVR) is the minimally invasive 
method for valve replacement. Being a relatively new procedure, it is executed in different 
fashions in different institutions. Accordingly, complications and results vary a lot. Further 
research is needed to identify ways to reduce complications. 
Aim: The aim of this project was to identify the milestones in the development of TAVR 
protocols in different institutions and to investigate how the different protocols affect the 
complication rates. 
Methods: A total of 1153 patients were included in the study. The data was collected from 
national TAVR registries in Sweden and the United States – Swedeheart and TVT registry 
respectively. The hospitals were compared regarding the entire TAVR process – from 
preparation for the procedure, through procedural differences in the cath lab to complication rates 
afterwards. 
Results: There were numerous significant periprocedural differences: anaesthesia type, 
procedure time, contrast use, rates of pre- and postdilation. There were no significant differences 
in stroke rates between the institutions. The rate of pacemaker implantation post-TAVR was 
significantly lower in Linköping than in New York (P=0.003) 1-Year mortality was significantly 
lower in New York than in Gothenburg. (P=0.02) 
Conclusion: Overall all three centers have low mortality and morbidity rates - lower than those 
reported in the literature. In addition, the TAVR results are non-inferior or superior to published 
surgical AVR series. Excellent TAVR results can be achieved using substantially different 
procedural protocols and perioperative logistics. It is feasible to avoid stroke, complete heart 
block and risk for kidney failure. Further research is needed to combine the best procedural 
practises to develop the ultimate TAVR. 
Key Words: TAVR, procedure, stroke, mortality, pacemaker  
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Introduction - Aortic Stenosis 
Aortic stenosis is one of the most common structural heart diseases. The prevalence increases 
with age and is in the elderly (>75 years old) population in epidemiological studies reported 
to be 7-12%.(1, 2)  
After the onset of symptoms (shortness of breath, angina pectoris, syncope), it is rapidly fatal. 
More than half the patients die within 12-18 months, unless they undergo aortic valve 
replacement (AVR). (3) It is therefore important for all physicians to have enough knowledge 
about this condition to correctly refer their patients for heart valve replacement.  
Transcatheter aortic valve replacement (TAVR) which is a minimally invasive procedure has 
been a major improvement in the treatment of aortic stenosis. At its introduction for more 
than a decade ago TAVR was considered a therapeutic option only for patients with a 
prohibitive risk for surgical AVR. Over the years, mostly due to an improvement in its safety 
TAVR has become a first-choice treatment for elderly people with moderate and recently 
even low perioperative risks.(4) Being a relatively young procedure TAVR is executed in 
different fashions in different institutions. Accordingly, complications and results vary a lot. 
Further research is needed to identify ways to reduce complications. 
Specific Aims of this Study 
The aim of this degree project is to identify the milestones in the development of TAVR 
protocols in different institutions and to investigate how the different protocols affect the 
complication rates, because better understanding could allow for more ubiquitous use of this 
breakthrough technology. The specific objectives analysed are pre- peri- and postoperative 
differences between the three hospitals. Are there any significant differences in the 
perioperative setup and techniques? Are there any significant differences in complication 
rates after TAVR – new permanent pacemaker implantation, stroke and mortality?   
 
5 
 
Introduction - Management of Aortic Stenosis 
Medical therapy: There is no effective medical treatment of aortic stenosis. For temporary 
symptom relief, diuretics and ACE inhibitors may be used but in the long term, the only 
definitive treatment is aortic valve replacement.  
  
Aortic valve replacement: Before the introduction of TAVR, the only way to replace the 
valve was with open heart surgery - surgical aortic valve replacement. There was no 
satisfactory alternative therapy for patients with a prohibitive risk for surgery. BAV may 
provide some symptom relief but it is only a palliative treatment in high-risk patients where 
no other invasive treatment is obtainable. (5)  
The first implantation of a transcatheter aortic valve in 2002 revolutionized the treatment of 
patients unsuited for surgery and it is considered a major milestone in interventional 
cardiology. 
Since then, the field of TAVR has been rapidly expanding - more than 350 000 procedures 
have been executed in over 70 countries. (6) 
TAVR has become much safer and more streamlined. The complication rates are getting 
smaller. While early studies comparing SAVR to TAVR at first found higher stroke rates in 
the later(7), more recent studies show no difference or even less stroke after TAVR. This is 
mainly due to the refinements in procedural techniques and devices. 
 
TAVR – About the procedure 
This minimally invasive procedure can be executed in different fashions but the general idea 
is to replace the damaged aortic valve with a new one without the need for a sternotomy. 
Instead it delivers the new valve through a catheter, somewhat similar to how a stent can be 
placed in an artery. Once the valve is in place, it pushes the native leaflets away and takes 
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over. 
Devices: There are multiple approved devices for TAVR. The two most commonly used in 
the centers compared in this study are the Edwards Sapien Heart Valve System (Edwards 
Lifesciences) and the Medtronic CoreValve Evolut. The main difference between the two is 
their construction, see images below. The Sapien is a bovine valve in a balloon expandable 
stainless-steel frame while the CoreValve is porcine and mounted on a self-expandable 
nitinol frame.(8)  
Figure 1 – Left to right: Sapien XT valve, Sapien 3 valve is a newer-generation valve that 
conforms more naturally to anatomy, thus having a better fit than the prior Sapien XT valve. 
The new conformation decreases paravalvular leak. Corevalve Evolut is a re-capturable valve 
that allows for recapturing and repositioning of the valve. (9) 
 
A randomized clinical trial (10) and published registry data (11, 12) comparing the self-
expandable and balloon expandable valve showed no significant differences in stroke, major 
vascular injury or mortality rates between the devices.  
The Medtronic CoreValve was however associated with a higher incidence of pacemaker 
implantation and aortic regurgitation post TAVR. (11-13)  
Nevertheless, the choice of device depends on patient anatomy, the operator’s preference, the 
center’s own experience and other factors.(8) 
7 
 
Access site: There is a number of access sites that can be used for a transcatheter valve 
implantation. The trans-femoral access using the common femoral artery is the most 
widespread. However, in cases with peripheral arterial disease or a presence of possible 
thromboembolic material in the aorta there are alternatives: the trans-apical, trans-aortic, 
trans-carotid, trans-subclavian and trans-caval approach. 
 
Indications for TAVR 
History: When the procedure was introduced in 2002 by prof. Alain Cribier, using the valve 
construction of Dr Henning Andersen, it was only performed on patients who were 
prohibitive risk for surgery for whom there was no alternative treatment aside from medical 
therapy. Excellent outcomes were reported in several studies showing that TAVR is superior 
to medical therapy (14) (15). El Bardissi et al showed that there was no difference in long-
term survival after this minimally invasive surgery as compared to an age- and gender 
matched population.(16)   
The PARTNER trial (14) compared standard therapy with trans-catheter implantation of a 
balloon-expandable valve (Sapien) in patients with severe aortic stenosis whom surgeons 
deemed unsuited for surgery. The results were as follows: 
• At 1 year, death from any cause was 30.7% with TAVR and 50.7% with standard 
therapy 
• The rate of death from any cause or repeat hospitalization was 42.5% with TAVR and 
71.6% with standard therapy 
• The rate of cardiac symptoms at 1 year was 25.2% in the TAVR group vs 58.0% in 
the standard therapy group 
A similar trial only with a self-expanding bioprosthesis (CoreValve) implanted in patients 
with prohibitive risk for surgery published a couple years later also showed significantly 
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better results with TAVR as compared to medical therapy. At 1 year, all-cause mortality or 
major stroke was 26% in the TAVR group vs 43% with standard therapy. (15) 
  
After it was shown to be a feasible procedure in patients with prohibitive risk for surgery, 
new trials started to investigate whether TAVR could be a better option than SAVR for 
patients with a high risk for surgery (7). TAVR and SAVR in this patient group were 
associated with comparable rates of survival at 1 year.  
  
As the results from this large-scale trial suggested that TAVR is non-inferior to SAVR in 
high risk patients, the next step was to examine if this would be true in intermediate risk 
patients as well.  
This was investigated in many trials, including PARTNER 2 (balloon expanding prosthesis) 
(17) and SURTAVI (self-expanding prosthesis) (18) 
In the PARTNER trial, transfemoral TAVR resulted in a lower rate of death and stroke than 
SAVR (hazard ratio, 0.79; 95% CI, 0.62 to 1.00; P=0.05). Transthoracic TAVR resulted in 
similar outcomes. The pattern of complications differed between the procedures. In both 
trials, surgery resulted in higher rates of acute kidney injury, severe bleeding and new onset 
atrial fibrillation while TAVR was associated with more vascular complications and 
paravalvular aortic regurgitation. Lower mean gradients and larger aortic valve areas as well 
as faster recovery and shorter ICU & hospital stay were observed post TAVR. 
These satisfying results led to the approval of TAVR as an alternative to surgery in 
intermediate-surgical risk patients by the American Heart Association and American College 
of Cardiology in 2017. The focus has now shifted to low risk patients with a goal to expand 
TAVR to all-risk patients. (19)  
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A Scandinavian randomized trial published in 2015 found no significant difference between 
TAVR and SAVR in regards to stroke, myocardial infarction or death from any cause at 1 
year in low risk patients. (4) There are large ongoing trials for low risk patients in the United 
States at the moment. 
It seems to be just a matter of time before TAVR manifests as an option for aortic valve 
replacement regardless of surgical risk score. However, some essential questions considering 
paravalvular leak, leaflet thrombosis, valve longevity and the need for new permanent 
pacemaker post TAVR need to be addressed. (19) 
  
The indications above include symptomatic patients. In asymptomatic patients with severe 
stenosis, the question of valve replacement is less clear. Rosenhek A et al. suggest that 
generally it is relatively safe to postpone surgery until symptoms develop. It seems 
improbable that the potential benefit of valve replacement could outweigh the risks associated 
with the surgery. However, patients identified with a very poor prognosis, for example with 
severe valvular calcification and rapid increase in aortic-jet velocity should be considered for 
earlier intervention.(20) 
 
Patients with severe, non-symptomatic aortic stenosis are frequently referred for TAVR prior 
to other major surgeries in order to lower their anaesthesiologic risks.  
 
Even patients with a bicuspid aortic valve or a degenerated surgical bio prosthesis can 
undergo TAVR. The latter is a so called “valve in valve” (VIV) TAVR and it has been shown 
to generate excellent outcomes. (21) 
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Recently the technique has also been utilized in the mitral position to repair mitral 
regurgitation or stenosis (22, 23) 
 
In summary, available data from large randomized trials and registries suggests that in terms 
of mortality, TAVR is superior to medical therapy in symptomatic patients at extreme 
surgical risk (14), non - inferior or superior to surgical AVR in high risk patients (24, 25) and 
non - inferior or superior (transfemoral access) in intermediate risk patients.(24) The 
evidence for superiority of TAVR over SAVR in low risk patients is not very strong yet but 
there are large ongoing randomized trials.  
Asymptomatic patients should not undergo aortic valve replacement with the exception of 
specific situations described above.  
 
Guidelines: 
The current guidelines on choosing between surgical and transcatheter aortic valve 
replacement by the American Heart Association for high risk patients recommend that a heart 
valve team involving a multidisciplinary group of professionals collaborates to provide 
optimal patient care. They state that “the patient’s values and preferences, comorbidities, 
vascular access, anticipated functional outcome, and length of survival after AVR should be 
considered in the selection”. 
Regarding symptomatic patients with an intermediate surgical risk, TAVR is stated to be a 
reasonable alternative to surgical AVR, depending on patient-specific procedural risks, 
vascular access, comorbid conditions, expected functional status after AVR and patient 
preferences. (26) 
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The European guidelines provided by the European Society of Cardiology (ESC) also 
emphasise that the decision between surgical AVR and TAVR should be made by a heart 
team in a heart valve centre with surgeons and cardiologists. Risks and benefits of both 
procedures should be weighed and factors like age, comorbidities, anatomy, local experience 
and outcomes should be discussed.   
Similarly, to the American guidelines, the indications for TAVR broadened in 2017 to 
include patients at intermediate surgical risk. This promises to increase the population 
suitable for TAVR globally.  
The guidelines point out that currently available data favours TAVR in patients at increased 
operative risk. Nevertheless, exact criteria for the decision between TAVR and SAVR is not 
well defined. Instead they refer to careful evaluation of every case by the heart team.(27)  
Aspects to be considered by the Heart Team for the decision between SAVR and TAVR in 
patients at increased surgical risk are summarized in a table attached in the appendix below. 
 
Complications 
Stroke 
Stroke is a rare but most feared complication, associated with severe disability and high 
mortality.(28) It is mainly confined in the peri-procedural and 30-day post-TAVR period. A 
possible cause of stroke in TAVR is dislodgement of atheromatous, calcific plaques.(29) 
Catheter manipulation in the aorta or during crossing of the calcified valve may also cause 
scraping of debris. Smaller and more flexible catheters are developed to prevent this. Balloon 
pre-dilatation of the native valve which crushes the calcified native valve may also increase 
the risk of cerebral embolism. A few years ago (2011 in Linköping, Sweden), operators 
began to omit pre-dilatation in balloon-expandable prosthesis to streamline the procedure, 
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reduce the number of pacing periods and shorten OR-time. Their experience show that it is 
safe and feasible.(30, 31)  Another possible cause of stroke is build-up of thrombi on 
catheters or on the prosthesis during implantation. Heparin is therefore administrated during 
the procedure. 
Operator experience is another factor affecting the outcomes.(32) 
For stroke prophylaxis, improved design of the procedure, cautious patient selection and 
antithrombotic strategies during and after the procedure are crucial. The valve and delivery 
systems are continuously refined and new embolic protection devices are produced.   
The 1-year incidence of stroke post TAVR is in large recent European meta-analyses (9786 
and 29034 patients respectively, both CoreValve and Sapien, TF and TA approach) reported 
to be approximately 3% (28, 33). An older article based on 12182 patients from 299 US 
hospitals who underwent TAVR between 2011 and 2013 reported a stroke rate of 4.1%(34). 
The incidence of stroke is consistently decreasing and is as mentioned previously comparable 
with SAVR.(24, 32-38)  
Regarding antithrombotic therapy post TAVR, there is no consensus yet, due to lack of 
proper studies so far.(39) Current AHA/ACC guideline recommendation is ASA and 
Clopidogrel for 6 months post TAVR.(40) Patients being on anticoagulants for other reasons 
before TAVR either continue on anticoagulants only, or combine them with one anti-platelet.  
Cerebral protection devices have not yet shown any positive clinical effects (41, 42) but there 
are reports suggesting a significant decrease of new ischemic cerebral lesions.(42, 43)  
It is interesting to further investigate the stroke rates correlation with different operative 
techniques and medications.  
 
Pacemaker 
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Conduction abnormalities are a common and serious complication of TAVR. Recent reports 
suggest permanent pacemaker (PPM) implantation post-TAVR increases exacerbation of 
heart failure, length of ICU stay and even overall mortality.(44, 45) It also exposes patients to 
potential complications of the implantation procedure itself. The need for new PPM 
implantation is one of the complications that still in most centres is higher in TAVR than in 
surgical AVR, which makes it an interesting subject to study. In the PARTNER2 trial with 
balloon-expandable valve: 8.5% in TAVR and 6.9% in surgical AVR.(17) However, some 
centres have already reduced new PPM implantation rate under the surgical prevalence for a 
few years now. Also, some valve models, e.g. Symetis Accurate, have a very good PPM 
record. Furthermore, some patients are diagnosed with conditions being indications for a 
pacemaker during the evaluation for TAVR. Thus they may have a pacemaker implanted 
within 30 days after TAVR procedure not as addressing the TAVR complication but due to 
the conduction abnormalities discovered before TAVR.   
Current guidelines are unclear regarding the exact indications and timing of PPM 
implantation with the result that it is a controversial subject at this time. To eliminate this 
problem, more research regarding the role of PPM implantation in TAVR is needed. 
An analysis of the literature leaves one with more questions than answers. A recent review of 
40 studies found that the incidence of new PPM post-TAVR ranges between 2.3% and 36.1% 
which is incredibly variable.(46) The rate is higher with self-expandable devices compared to 
balloon-expandable. For new generation Sapien 3 device, the rate was between 4%(47) and 
24% (48), while the new Evolut R ranged between 14.7%, as reported by Kalra et al.(49) and 
26.7% in the SURTAVI trial (18). As the authors of the review point out, specific 
recommendations for implantation of each prosthesis are needed to reduce the rate of new 
PPM.  
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There are predisposing factors predicting conduction abnormalities affiliated with TAVR. 
Clinical studies show that anatomical factors like thick baseline interventricular septum 
(>17mm), non-coronary cusp thickness >8mm and small LVOT diameter are associated with 
higher risk of PPM. (50, 51). Furthermore, the volume of LVOT calcification below the level 
of right and left coronary cusps (52), pre-existing right bundle branch block, large ratio of the 
prosthesis to LVOT diameter(measured in mid-systole), small left ventricle end diastolic 
diameter (45) and low valve position (depth of implantation >25.5% with Sapien 3 (53)) are 
other independent predictors. Moreover, AV-block I, bifascicular block and atrial fibrillation 
with slow ventricular rate increase the risk.  
New onset of LBBB post-TAVR increases PPM implantation (54), heart failure 
hospitalization and mortality.(55) 
A German study by Hoffmann et al. concluded that LVEF improves after TAVR in absence 
of new conduction defects, while patients with new conduction defects do not experience 
improvement in LVEF at follow up. (56) 
Mechanisms of conduction system injury have been shown to include compression, trauma, 
infarction or haemorrhage.(57)  
The most common conduction disturbances after TAVR are AV-block (AVB) and left bundle 
branch block (LBBB). 
Current guidelines from the ESC recommend considering PPM in patients with complete 
heart block (CHB) and high grade AVB if they persist 7 days after TAVR. However, most 
studies recommend PPM implantation 24-48 hours after the procedure if CHB was noted in 
the periprocedural period to not delay ambulation and discharge and to prevent morbidity 
from immobility with the temporary pacemaker. The ACC does not provide any official 
guidelines on this matter and PPM implantation is left to the discretion of the physician.  
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It is interesting to investigate if there are any procedural factors that have the potential to 
minimize conduction abnormality after TAVR. Therefore, one of the aims of this study is to 
investigate which changes in TAVR protocol lead to a decrease in PPM implantation rate 
post TAVR. 
 
Material and method 
Total of 1153 patients were included in the study. The data was collected from national 
TAVR registries in Sweden (Gothenburg and Linköping) and in the United States (New 
York), Swedeheart and TVT registry respectively. Three university hospitals were included 
in the study: New York Presbyterian Hospital, Sahlgrenska University Hospital in 
Gothenburg and Linköping University Hospital.  
 
Referral population to the hospitals: 
Sahlgrenska University Hospital gets referrals from an area covering approximately 1.8 
million people. 
Linköping University Hospital covers an area of around 1 million people.  
The size of the referral population to Weill Cornell Presbyterian Hospital was difficult to 
determine. Patients from Manhattan, Brooklyn, Bronx, New Jersey and Upstate NY are 
referred to all the different hospitals in the area – Weill Cornell Presbyterian, Columbia 
Presbyterian, Mount Sinai, Lenox Hill, NYU, Montefiore, NYP Methodist, Northwill.  
 
The inclusion criteria were: patients who have undergone TAVR with either Edwards or 
Medtronic valves between 2014 and 2018. The reason for the dates chosen was that data from 
the period before 2014 was not complete in regard to the endpoints of pacemaker and stroke 
in the American TVT registry. The choice of valves studied was made to be able to compare 
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the results based on valve type. Even though there are many commercially available valve 
types in Europe, only Edwards and Medtronic valves are approved in the United States.  
 
The registries are filled out by either the cardiologist performing the procedure – in Sweden, 
or a nurse practitioner involved with the cases – in New York. They are considered very good 
quality and all patients, besides research cases in the PARTNER trial in New York 
undergoing the procedures are followed up. The way the registries are filled out differs 
between the hospitals. In the Swedish institutions, the data is systematically inserted directly 
after the procedure by the cardiologist performing the procedure. The in-hospital 
complications are added at discharge – in Linköping by the anaesthesiologist and in 
Gothenburg by the cardiologist. In New York Presbyterian, a nurse practitioner fills out the 
registry using the data in the patient chart usually within a month of the procedure.  
Of the 1153 patients, 547 were taken from the TVT registry in New York (398 Sapien & 149 
Medtronic), 350 from Linköping (Sapien) and 256 from Gothenburg (Medtronic). See figure 
1 below. 
Figure 2 – Number of TAVR cases per institution over time according to valve type 
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The data was de-identified from names and personal identification numbers.  
It was organized to be outlined in similar ways from the different registries to make the 
statistical analysis possible. Patients who received valves different from Edwards or 
Medtronic and valves in all extra-aortic positions (mitral, tricuspid, pulmonary, caval) were 
excluded.  
 
Parameters analysed to describe the epidemiology of patients in the different institutions 
were: age, sex, percentage of hypertension, diabetes, chronic lung disease, myocardial 
infarction prior to the procedure, prior heart surgery and stroke in the previous medical 
history. Chi square test was used for statistical analysis and p-value < 0.05 was considered 
statistically significant. As the table below shows, the populations were very similar in regard 
to all factors except for history of hypertension which showed to be higher in NYP than in the 
Swedish hospitals. 
Figure 3 - Epidemiology of patients included in the study 
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Patients with hypertension were overrepresented in New York (p<0.0001) while patients in 
Gothenburg had significantly higher proportion of heart surgery prior to TAVR (p=0.02) 
There was no significant difference in diabetes, chronic obstructive pulmonary disease and 
history of stroke among the patients in the three institutions (p-value 0.55, 0.18 and 0.52 
respectively). The original plan was to look at proportion of pacemaker before the procedure 
as well but this was not documented in the registries. 
Table 1 - Demographics and Baseline Characteristics of TAVR patients 
Characteristic New York Linköping Gothenburg 
 (N=634) (N=351) (N=260) 
Male Sex – no. (%) 286 (55%) 171 (49%) 145 (56%) 
Hypertension – no. (%) 501 (79%) 225 (64%) 178 (68%) 
Diabetes – no. (%) 178 (28%)* 107 (30%) 69 (27%) 
Prior Heart OP – no. (%) 132 (21%)** 65 (19%) 72 (28%) 
Chronic Obstructive 
Pulmonary Disease – no. (%) 
99 (16%)*** 68 (19%) 37 (14%) 
Stroke – no. (%) 64 (10%)× 40 (11%) 33 (13%) 
*Data missing for 2 patients; **Data missing for 4 patients; ***Data missing for 3 patients; 
×Data missing for 2 patients 
  
There were no statistically significant differences in average age of patients at the time of the 
procedure in the three institutions: 82 years at NYP, 80 years in LKPG and 81 in GBG. 
 
Method 
The three hospitals were compared regarding the entire TAVR process – from preparation for 
the procedure, through procedural differences in the cath lab to complication rates afterwards.  
 
The procedural differences analysed were:  
• the set up in the cath lab – personnel involved in TAVR in regard to which specialty – 
cardiologist vs cardiothoracic surgeon is performing the procedure 
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• anaesthesia type used 
• total time of the procedure 
• contrast volume used during the procedure 
• fluoroscopy time 
• echo-guidance  
• number of arterial accesses 
• balloon aortic valvuloplasty  
• post-dilatation 
• access to cardiopulmonary bypass machine 
 
The differences in preparation for TAVR – variables studied were: 
• decision making for TAVR vs sAVR – who is in charge? 
• clinical visits before TAVR – physical exams, tests – TTE, TEE, ECG, CT, cardiac 
cath, x-ray, labs 
• heart team rounds – when in relation to the procedure? Which categories of 
physicians are involved?  
 
The complication rates analysed were: 
• new PPM implantation post TAVR 
• stroke  
• in hospital mortality 
• 1-year mortality 
• contrast induced nephropathy 
Special emphasis was laid on stroke, pacemaker and mortality rates for which the rates were 
analysed per year to recognize trend changes over time. 
20 
 
All the above endpoints were included in the registries. The definitions used for 
complications in the registries are as follows: 
New permanent pacemaker: 
New York: Conduction/Native Pacer Disturbance Req Pacer (In hospital & follow up): 
“Indicate whether patient developed a new dysrhythmia requiring insertion of a permanent 
pacemaker.” 
Gothenburg & Linköping: Indications for NPPM after TAVR in LKPG are consistent with 
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. The most 
common causes being acquired AV block grade III or II irrespective of symptoms, sinus node 
disease, incl. tachy/brady syndrome with symptoms or Afib with AV-block with symptoms.  
 
Stroke: 
New York: (In hospital & follow up): Definition taken from the FDA draft “Standardized 
Definitions for Cardiovascular Endpoints in Clinical Trials”: “An ischemic stroke is an acute 
episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal 
vascular injury as a result of infarction of central nervous system tissue. Haemorrhage may be 
a consequence of ischemic stroke. In this situation, the stroke is an ischemic stroke with 
haemorrhagic transformation and not a haemorrhagic stroke.”  
Gothenburg & Linköping: Stroke is defined as brain, spinal cord, or retinal cell death 
attributable to ischemia, based on pathological, imaging, or other objective evidence of 
cerebral, spinal cord, or retinal focal ischemic injury in a defined vascular distribution; or 
clinical evidence of cerebral, spinal cord, or retinal focal ischemic injury based on symptoms 
persisting ≥24 hours or until death with other aetiologies excluded. 
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In-hospital mortality:  
Linköping & Gothenburg: Defined as either occurring during the intervention or before 
discharge from the hospital. 
New York: Defined as status at discharge – alive vs deceased.  
 
1-year mortality: 
Linköping & Gothenburg: Defined in the registry as deceased within 365 days from the 
procedure date. The registry is linked to the national mortality-registry. 
New York: “1-year mortality” was deducted from information about follow-up status – alive 
vs deceased. That data was organized to pinpoint the date of death and then calculated for the 
proportion of patients deceased within 365 days from the procedure date. 
 
Statistical Analysis: 
The data was divided according to the valve type used – Edwards vs Medtronic for the 
analysis of incidence of new PPM and stroke following TAVR for each of the valve types in 
the three centres.  
Chi square test (for categorical variables), t-test (to compare means) and ANOVA (for 
variation between more than two groups) were used for statistical analysis of all variables and 
p-value <0.05 was considered significant. Continuous variables are demonstrated as mean ± 
SD. Categorical variables are presented as frequencies. 
All statistical analysis was performed using IBM SPSS Statistics 25 and Excel 2016. 
 
Following data analysis, cath-lab visits were carried out and interviews were conducted with 
the operators to determine how they perform the procedures and to identify what changes 
they have made to their TAVR protocols. Subsequently, the different protocols were analysed 
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and compared to identify procedural differences and to explain the differences observed in 
results.   
 
Ethical Considerations 
There was no need for institutional ethical board consent for the planned study design. 
Neither for an informed patient consent. No individual patient data were to be disclosed to 
third parties.  The study had an observational and retrospective design. Basic principles for 
medical research enunciated in the Declaration of Helsinki were respected during the project. 
 
Results 
Table 2 – Procedural Data 
 
 
There was a significant difference in approach used for TAVR with higher rate of 
*no data available in the registry 
 NYP GBG LKPG 
General Anaesthesia 85% (536/628) 4% (11/260) 90% (317/351) 
Transfemoral access  89% (487/547) 98.8% (257/260) 85.5% (300/351) 
Procedure time (min) 113 ± 58 (n=628) 71 ± 27 (n=250) 48 ± 40 (n=351) 
Fluoroscopy time (min) 11.9 ± 9.0 (n=395) 20.1 ± 9.3 (n=260) 17.4 ± 14.1 (n=351) 
Contrast (ml) mean 48 ± 33 (n=378) 99 ± 60 (n=260) 7 ± 18 (n=351) 
BAV All TF but ViV 82.1% (211/257) 2.8% (10/351) 
Post-Dilatation estimated 5% * 16.9% (44/260) 4.6% (16/351) 
Echo guidance Y/N Y&N N Y 
No of arterial access 
sites 
2 femoral ± 1 
radial(if Sentinel) 
2 femoral/1 femoral 
+ 1 radial starting 
2018 
1 femoral 
No of operators and 
specialities 
1 CT surgeon 
1-2 cardiologists 
2 cardiologists 1 CT surgeon 
1-2 cardiologists 
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transfemoral access in GBG as compared to LKPG and NYP (p<0.0001). No significant 
difference between LKPG and NYP (p=0.1394) 
There was a significant difference in procedure time between LKPG and GBG (p<0.0001), 
GBG and NYP (p<0.0001) and LKPG and NYP (p<0.0001) 
The contrast use in LKPG was significantly lower than in GBG and NYP (p<0.0001 for both)  
At NYP the contrast use was significantly lower than in GBG (p<0.0001) 
The rates of predilation were significantly lower in Linköping than in Gothenburg 
(p<0.0001). There was 0% predilation in LKPG in 2015,2016 and 2017. 
There was significantly less postdilation in LKPG than in GBG (p<0.0001) 
 
As the graph below shows, there was a major difference in anaesthesia type used in the three 
institutions. Gothenburg stands out with almost no cases performed in general anaesthesia. 
Interestingly, the trends over time were opposite in New York and Linköping. While in New 
York the trend is to move towards more cases in monitored anaesthesia care (MAC), in 
Linköping after experimenting with both types, they chose to use general anaesthesia in most 
cases 2017.  
 
Figure 4 – Proportion of patients undergoing TAVR in general anaesthesia 
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Creatinine before and after the procedure was also analysed. Both change in creatinine in all 
patients and the percentage of patients with an increase of >25% from baseline, which is the 
definition of contrast induced nephropathy were analysed.  
The results were as follows: 
Table 3 - Creatinine changes and proportion of contrast induced nephropathy after TAVR 
 
The changes in creatinine before vs after the procedure were not significant in any of the 
three hospitals.  
There was however a significant difference in proportion of patients with >25% increase in 
creatinine between NYP and LKPG (p=0.007) 
In LKPG, a systematic approach aimed at the reduction of contrast usage had been employed 
resulting in the reduction of contrast volume per procedure as well as the fraction of 
completely contrast free procedures: history of 300 cases between 2008 and 2015: 
 
 NYP GBG LKPG 
Mean change in Creatinine 
before vs. after TAVR 
 
-2.5 (N=549) 
 
-10.4 (N=255) 
 
-7.9 (N=344) 
Percentage (%) >25% 
increase in Creatinine after 
TAVR 
 
9.1% (N=549) 
 
4.7% (N=255) 
 
4.0% (N=344) 
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Figure 5 – Mean contrast use during TAVR 
in LKPG 2011-2018 
Figure 6 – Proportion of patients operated 
without contrast during TAVR 2011-2018 
25 
 
 
Since 2008, no clinically overt AKI following TAVR has been reported in LKPG as a result 
of this approach. The mean contrast usage stands at 8mL per procedure. Nowadays, 75% of 
TAVRs in LKPG are performed without contrast. 
TAVR Protocols 
Table 4 – Workup for TAVR in the three hospitals 
 
At New York Presbyterian Hospital, the preparation for TAVR includes a physical 
examination and evaluation of symptoms by two cardiothoracic surgeons to determine 
whether the patient is a good candidate for TAVR. 
 
In Sahlgrenska University Hospital, the TTE is used for heart function assessment, grading of 
aortic stenosis and assessment of other valve problems. The CT with contrast is used to 
inspect a.femoralis, a.iliaca, aorta and to measure annular size for selection of the appropriate 
NYP GBG LKPG 
Appointment with two 
cardiothoracic surgeons 
Appointment with 
cardiologist 
Appointment with 
cardiologist 
TTE TTE TTE & TEE 
CT angiography CT with contrast CT with contrast 
Cardiac catheterisation  Coronary angiogram  Coronary angiogram 
ECG ECG ECG 
Labs – complete blood 
count, urine culture, NT 
BNP, troponin I, complete 
metabolic profile w glucose 
plasma, GFR, bilirubin, CK, 
INR, urinalysis dipstick 
with microscopic exam 
Labs – complete blood 
count, electrolytes, 
NTproBNP, creatinine, 
GFR, INR 
Labs – complete blood 
count, electrolytes, 
NTproBNP, creatinine, 
GFR, INR 
Chest xRay   
Ultrasound of carotids (for 
Sentinel device screening) 
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valve size. As for the coronary angiogram, patients >85 yr do not routinely undergo coronary 
angiogram unless they have symptoms of ischemic heart disease.  
 
At the heart team rounds in GBG, a general cardiologist, an interventional cardiologist, a 
cardiothoracic surgeon and a thoracic anaesthesiologist attend the meeting.  
Factors that are taken into account when discussing TAVR vs sAVR are; age – the default for 
patients >85 is TAVR. Younger patients are referred for TAVR if they have pronounced 
comorbidities (e.g. renal insufficiency, anaemia, cancer, lung disease, calcium in aorta etc.) 
or if they have previously undergone thoracic surgery.  
 
In Linköping University Hospital, aside from symptomatic patients, some asymptomatic 
patients are evaluated - those with severe aortic stenosis scheduled for a major surgery, where 
TAVR before the major surgery improves the safety of the subsequent surgery. 
The TTE & TEE is in LKPG used for; grading of AS, valve morphology, sizing, ascending 
aorta diameter, identifying other cardiac problems requiring repair, identifying 
thromboembolic material, ventricular function, pericardial effusion, bulging septum. 
The CT with contrast is used for; valve sizing, valve morphology, valve calcification pattern, 
annular rupture risk, aortic dimensions, coronary artery occlusion risk evaluation, access 
evaluation, thromboembolic material in aorta, iliac-femoral vessel diameter and tortuosity 
and pleural effusion. 
The ECG is made to evaluate if the patient has pacemaker indications before TAVR and 
recognize the risk factors for post TAVR new PPM mentioned in the introduction. 
 
The afternoon on the day before the procedure in LKPG, the heart team consisting of 
cardiologists, cardiothoracic surgeons, radiologists and anaesthesiologists attends a meeting 
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where the case is discussed, CT and echo images are presented (by radiologist and 
cardiologist respectively) and the team agrees on approach, anaesthesia type, valve type and 
size. Furthermore, the degree of addressing a possible complication is discussed – use of 
cardiopulmonary bypass, conversion to open heart surgery and HLR. 
 
TAVR Procedure GBG 
The procedure is performed by two cardiologists. The rest of the crew in the operating room 
consists of three nurses: 1 OR nurse assisting in the procedure, 1 nurse handling the 
medications and 1 nurse preparing the valve. 
Uniquely for Gothenburg, there is no anaesthesiologist in the operating room – most cases are 
performed without sedation.  
A temporary pacemaker is placed through v.jugularis interna by one of the cardiologists. 
The default valve is Medtronic Evolut R. A.femoralis is punctured with ultrasound guidance. 
6F introducer is inserted in the right a.radialis (since beginning of 2018 – a.femoralis 
previously). 14F in a.femoralis. Straight end regular guidewire is used to cross the valve with 
help of AL1 catheter. Change to pre-curved stiff guidewire through pigtail, nowadays most 
often confida guidewire. Balloon-predilatation is almost always performed. The valve 
position is controlled with contrast in aorta + sometimes with echocardiography.  
A.femoralis is closed with different devices: Proglide, Prostar or MANTA device. 
 
There is no cardiopulmonary bypass machine in the operating room.  
Pacemaker is left in place for 1-2 days depending on ECG changes.  
 
TAVR Procedure LKPG 
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In Linköping, the procedure is by default performed in general anaesthesia (GA). Local 
anaesthesia is only employed in patients with high risks for general anaesthesia or in cases of 
staff/ICU bed shortage.  
The procedure is performed by a cardiologist and a cardiothoracic surgeon. 
Right ventricle (RV) electrode is placed through v.jugularis interna. An alternative is pacing 
through the guidewire in LV (usually in cases with Symetis valve) or RV pacing through the 
electrode inserted via femoral vein. The next step is ultrasound guided puncture of 
a.femoralis communis – one side only. Heparin is given with target Activated Clotting Time 
(ACT) of 250-350seconds. ACT check-up every 30 minutes. 
 An introducer sheath is introduced into the common femoral artery. Secondly, a guidewire 
and the delivery system over the guidewire is introduced to the descending aorta. The valve is 
mounted on the balloon in the descending aorta, no guidewire is present in the ventricle at 
that moment to minimize the risk for ventricular rupture. TEE check-up is made to make sure 
no embolic material is engaged on the system. 
TEE surveillance during the whole procedure is default when GA is the case. In local 
anaesthesia cases TTE is used. Intracardiac echocardiography (ICE) is also an option, 
although rarely used. 
A soft tip guidewire (Advantage guidewire is default, Straight tip Terumo guidewire is an 
alternative) is steered through the valve under TEE guidance. Valve is placed into the 
anatomical position with TEE- and fluoro-guidance. Guidewire is pulled back into the system 
in order to prevent ventricular rupture, ventricular extra systole and damage to the mitral 
apparatus, as well as to harmonize the prosthesis/native valve movement. Under rapid 
ventricular pacing the valve is deployed. The TEE is used to evaluate valve function, 
paravalvular leak (PVL), ventricular function, coronary ostia patency and volume status. 
In a case of PVL more than mild post-dilatation is done under rapid ventricular pacing. 
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The system is extracorporated and the femoral artery is closed with one Prostar XL or two 
Proglide vascular closure devices. 
What is unique in Linköping is that no contrast media is the default way, no contralateral 
access is the default way, no stiff guidewire is present in LV during a prolonged period of 
time and no BAV is the default. 
  
Cardiopulmonary bypass machine and perfusion technician are available in the operating 
room at all times. 
 
TAVR Procedure NYP 
At NYP the crew in the cath lab consists of around 11 people: a cardiothoracic surgeon, an 
interventional cardiologist, a cardiology resident, an anaesthesiologist + anaesthesiology 
resident, two cath lab nurses, a radiology technician, an angioplasty specialist (scrub 
technician), two people from Edwards/Medtronic preparing the valve. If the procedure is 
done under general anaesthesia, there is also an echo technician and an echo attending.   
The procedural steps at NYP are as follows: Defibrillator pads are applied to anterior and 
posterior chest wall. Anaesthesia mask is applied if general anaesthesia case. Analgesia is 
administered by cardiac anaesthesiologist. Radial A-line is placed. Intubation if general 
anaesthesia. TEE probe – general anaesthesia cases/TTE for monitored anaesthesia care cases 
– Baseline echo evaluation. Central line placement. (Advance swan probe - for right heart 
pressures - select cases, usually general anaesthesia) Sterile field is set up. 
2-3 access sites: large bore (14- 18F) arterial on one side, 6F arterial + 7F venous on 
opposite, right radial or brachial for Sentinel cerebral protection device in selected cases. 
Transvenous pacemaker, a test of pacemaker is made. Pigtail through the 6F arterial sheath 
for angiogram. Heparin given to achieve ACT > 250. 
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Introducer sheath for balloon expandable, in line sheath for self-expandable valves. Wire is 
inserted to cross the valve. When crossed - AL1/MB1 catheter across the valve. Wire is 
exchanged for either a Confida wire or Lunderquist wire. Balloon angioplasty under rapid 
pacing is next. Delivery system – valve positioned using aortography. New angiogram to 
position. Valve deployment under rapid ventricular pacing. Post deployment injection. 
TEE/TTE to assess valve function assess for any paravalvular leak and measure mean 
gradients. Removal of arterial sheaths, deployment of Perclose, haemostasis. 
Removal of venous sheaths, application of manual pressure. Transfer to ICU for routine post 
TAVR care. 
 
Post-TAVR 
 Table 5 – Protocols post-TAVR – antiplatelet therapy & follow up visits 
 
 
Outcomes - Complication Rates & Mortality 
Stroke: 
 NYP GBG LKPG 
Antiplatelet therapy Dual antiplatelets 6 
months 
Dual antiplatelets 3 
months 
Dual antiplatelets 6 
months 
If patient is already 
on anticoagulants for 
atrial fibrillation 
Occasionally one 
antiplatelet is added 
Occasionally one 
antiplatelet is added 
No antiplatelet is 
added  
Follow up visits and 
echocardiography 
Cardiologist 2 weeks 
post TAVR. Surgeon 
30 days post op. 
Echo at 30 days & 1 
year  
Cardiologist & echo 
at 30 days, 6 months, 
1 year and yearly 
thereafter 
Cardiologist & echo 
at 30 days, 6 months, 
1 year and yearly 
thereafter  
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Figure 7 – Proportion of stroke after TAVR in LKPG and NYP using Edwards valves 
There was no statistically significant difference between stroke rates post TAVR with 
SAPIEN valves in New York and Linköping. 
3 out of 350 (0.86%) patients who underwent TAVR with a SAPIEN valve in Linköping 
2014-2017 were reported with stroke as a complication. In New York, the number was 3 out 
of 398 (0.75%) (p=0.8743). 
 
 
Figure 8 – Proportion of stroke after TAVR in GBG and NYP using Medtronic valves 
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There was no statistically significant difference in stroke rates post TAVR with Medtronic 
valves in New York and Gothenburg 2014-2017 (p=0.8809). 
In New York, 2 out of 149 (1.34%) patients experienced a stroke, in Gothenburg there were 3 
out of 256 (1.17%) cases. 
Pacemaker Results:  
 
Figure 9 – Proportion of new PPM after TAVR in LKPG and NYP using Edwards valves 
In total during the four-year period 2014-2017, there were 350 cases of SAPIEN valve 
implantation in Linköping University Hospital and 398 cases in New York Presbyterian 
Hospital. 6 patients (1.71%) in Linköping required a permanent pacemaker implantation after 
the procedure. 25 patients (6.28%) required a PPI in New York. The difference in PPM 
implantation rates post TAVR with Sapien valves was statistically significant (p=0.0032) 
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Figure 10 – Proportion of new PPM after TAVR in GBG and NYP using Medtronic valves 
PPI was required in 11 of 149 (7.38%) patients post TAVR with Medtronic valves in New 
York 2014-2017 and 28 of 256 (10.94%) patients with Medtronic valves in Gothenburg. 
No statistically significant difference was found for proportion new permanent pacemaker 
post TAVR with Medtronic valves between New York and Gothenburg 2014-2017 
(p=0.3198) 
 
 
Figure 11 – Proportion of in-hospital-mortality following TAVR per year 
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In-hospital mortality was in total during 2014-2017 found to be 1.26% in NYP, 1.55% in 
Gothenburg and 1.99% in Linköping. There was no significant difference in mortality 
between the three hospitals (p-value 0.668).  
 
 
Figure 12 – One-year mortality after TAVR in GBG, LKPG and NYP over time 
There was no data available in the registries regarding 1-year mortality from 2017 since the 
data was extracted in January 2018.  
The mortality dates in Swedeheart and TVT registry are taken from national mortality 
registries and social security death index respectively.  
25 of 368 (7%) of patients that data was available for regarding mortality 2014-2017 in NYP 
died within a year after TAVR. 28 of 252 (11%) died within a year in LKPG between 2014 
and 2017 and 21 of 156 (13%) died within a year in GBG. 
The difference in one-year mortality between the three institutions was significant (P=0.0347) 
The difference between LKPG and NYP was not significant (p=0.0814). LKPG – GBG was 
not significant (p=0.5802). NYP-GBG was significant (p=0.0216). 
There was a big drop in mortality rates in all three hospitals between 2014 and 2015. As this 
was hypothesized to be explained by incorporating intermediate risk patients as opposed to 
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only operating high risk, the risk profiles were analysed as well. The risk score used in NYP 
is STS-score while the Swedish hospitals use Euroscore II. The percentage of non-high-risk 
patients was analysed. Non-high-risk were defined as Euroscore II <5% or Sts-score <8%. 
The table below shows the results: 
 
 
Figure 13 – Proportion of non-high-risk patients undergoing TAVR per year 
Surprisingly the percentage of non-high-risk patients was highest in New York during the 
whole period 2014-2017. It was significantly higher in New York than in Linköping and 
Gothenburg (p<0.0001 for both). 
 
Vascular complications were documented in very 
dissimilar ways in the different registries which 
made statistical comparison unfeasible. In any case, 
during the production of this project, the noted 
proportion of major vascular complications did 
seem to be relatively low. 
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Discussion 
1. Epidemiology 
The baseline characteristics among patients in the three institutions were quite similar. The 
patients at NYP had significantly higher proportion of hypertension prior to the procedure 
and the proportion of men was higher in LKPG but aside from this, there were no differences 
in the populations. Mean ages at the time of the procedure were comparable as well. 
Proportion of myocardial infarction (MI) before TAVR was also analysed. However, due to 
dissimilar definitions in the registries – in Sweden, only MIs within 3 months before the 
procedure were recorded while NYP recorded all MIs, the results were not analogous. Of 
note, there was no significant difference in proportion of MIs between the Swedish hospitals.  
 
2. Procedural differences 
1. Anaesthesia type used for TAVR  
Principal differences exist in the type of anaesthesia used for TAVR among institutions. 
While almost all cases in 2017 in Gothenburg were done under local anaesthesia (LA) 
without any sedation, almost all cases in Linköping were performed under general 
anaesthesia (GA). As for New York, there was a 1:1 ratio between GA and monitored 
anaesthesia care (MAC). 
One could argue which approach is best. Arguments against GA include: no symptomatic 
feedback from the patient in case of vascular injury or a neurological complication; there 
could be a lack of physiological blood pressure recovery after rapid ventricular pacing (RVP) 
resulting in prolonged hypotension which can be followed by catecholamine induced 
hypertension; higher procedure cost; the involvement of more personnel compared to LA, 
high stress levels among patients regarding concerns about GA prior to a procedure.  
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On the other hand, GA brings the advantage of TEE use during the procedure which is one of 
the factors contributing to a low new PPM rate, better patient comfort due to the absence of 
groin pain during puncture and being asleep during RVP. 
Another factor contributing to the higher frequency of GA in LKPG and NYC is the fact that 
all TA-TAVR are done under GA.  The trans-apical approach is not utilized in GBG which 
contributes for the minimal use of GA as compared to the two other centres.  
Analysing the dynamics over time, it was interesting to find that the general trend early on 
was toward LA, however with time LKPG reversed it back to GA.  
GBG makes logistics associated with the procedure much simpler and more cost efficient 
thanks to the usage of local anaesthesia. 
2. Procedure time 
The shortest procedure time was in LKPG, followed by GBG and NYP, respectively. The 
fewer intraprocedural steps in LKPG perhaps accounted for the shortest procedural duration. 
Those fewer step included: 
o 1 arterial access 
o skipping over going through the valve with a catheter  
o skipping over the wire exchange for the delivery system 
o no pre-dilatation  
o hardly ever post-dilatation  
o all angiographic steps virtually absent  
The way by which the three institutions define procedural times varies, which also could 
account for the difference seen in the results between Sweden and USA. NYP defines 
procedure time as the time from anaesthesia induction until the moment the patient leaves the 
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procedure room. Bed shortage in the ICUs lead to prolonged time in the procedure room 
which inaccurately reflects as a longer procedure time in the registry.   
In LKPG and GBG the stop time of the procedure is defined as the time when the artery is 
closed. The start time in GBG and LKPG is defined as the time of insertion of pacemaker 
introducer in the neck vessel.  
Since total time in the cath lab has been shown to be one of the significant procedural 
predictors (58), aiming for the shortest possible procedure time should be one of the goals for 
improving the safety of TAVR. 
3. Fluoroscopy time 
NYP reported the shortest fluoroscopy time.  
The reasons for aiming for the shortest time possible is to minimize the exposure to radiation 
– both to the patient and the provider, as well as to make the procedure more cost effective. 
4. Pre- and post-dilations 
GBG and NYP have higher pre-dilation rates in comparison to LKPG. The probable 
explanation is they use a self-expanding valve and not a balloon mounted one. Self-
expanding valves have lower radial strength and accordingly cannot open a highly calcified 
valve as well as their balloon mounted counterparts. BAV is employed to overcome this 
issue. Also, directly after valve deployment the self-expandable valves suffer from PVLs 
more often and post-dilation is needed to address them. 
The possible disadvantages of BAV (listed below) are reasons why TAVR without BAV may 
be a better option: 
i. Rapid Pacing  Hypoperfusion (cerebral and myocardial). 
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ii. Stiff guidewire in the left ventricle  risk of perforation and 
arrhythmia. 
iii. Passage nearby embolic sources at aortic arch with BAV system. 
iv. Risk of major vascular complications  
v. Contrast (if used for sizing or from balloon rupture). 
vi. Longer procedure and fluoroscopy times, higher costs. 
vii. Conduction disturbance is more likely with BAV. (59) 
 
5. Contrast media volumes 
What was unique in LKPG is that not using contrast was the default. TAVR patients are often 
sensitive to contrast administration due to: 
• overt renal failure 
• subclinical reduced glomerular filtration accompanying their increased age 
and low cardiac output  
• medications (metformin, diuretics) 
• recent contrast exposure during aortic and ilio-femoral CT screening and 
coronary angiography 
Due to the risks mentioned above, patients become more prone to developing acute kidney 
injury (AKI), namely contrast induced nephropathy.(60)  
The Source 3 Registry reported 27-32% renal insufficiency in baseline population 
characteristics.(61) 
A meta-analysis of 5971 patients has shown that AKI leads to a 5-fold increase in 30-day 
mortality and 3-fold increase in 1-year mortality.(62) Therefore, efforts should be made to 
minimize the rate of AKI post-TAVR. 
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6. Intraprocedural echo-guidance is virtually used in all cases in LKPG, both for puncture 
and during the procedure, while in GBG it is used during the arterial puncture only. NYP 
alternates in its usage. Echo-guidance can be employed during following procedural 
steps: 
During arterial puncture to ensure: 
• Common femoral artery is 
punctured and not the superficial 
femoral 
• Central luminal access 
• Puncture area is free from calcified 
plaques on the anterior wall of  
the artery 
• There is no transvenous puncture 
• Lumen diameter is sufficient 
 
TEE during TAVR in LKPG is used for:  
• guiding the system in the ascending aorta 
• cusp alignment 
• avoiding thromboembolism 
• guiding valve crossing with guidewire and delivery system 
• prevention of AV-block 
• guiding the height of valve placement 
• screening for a coronary artery occlusion 
Figure 15 – Showing the concept of ultrasound guided arterial 
puncture. Courtesy of Nature Reviews, Cardiology  
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• monitoring ventricular function with regional wall movement abnormalities and 
volume status 
• pericardial effusion and pleural effusion evaluation  
• valve function and detecting para-valvular leakage 
 
Nonetheless, most of these factors can be controlled by alternative methods such as 
angiography, the use of reference catheters or calcifications as landmarks, invasive pressure 
monitoring and the analysis of a combination of vital signs.  
 
The extensive use of ultrasound in LKPG is part of a general approach in many procedures. 
The goal is to minimize the number of vascular access sites, minimize contrast amount and 
use more 3D imaging. This approach is more expensive and requires more personnel. 
 
7. Number of arterial access sites  
GBG and NYP use two arterial access sites per patient while LKPG uses one, as the echo-
guidance technique is used for valve placement. The second access site is normally used for 
contrast injections and for a pigtail catheter insertion into the aortic root in order to get a 
landmark for appropriate valve placement. In LKPG the TOE operator shows the landmarks 
instead.  
Reducing the number of access sites may reduce the risk of vascular complications and 
shorten procedural time. 
 
Cost-effectiveness of this approach is not warranted because the cost of echo-operators and 
equipment counterbalances the savings on the catheter site. 
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There are two infrequent situations where a second arterial access may be needed in LKPG as 
well: 
a. Snare is needed for valve passage (valve in valve, bicuspid, dilation of the 
ascending aorta) 
b. For aorto-iliac or femoral artery balloon occlusion in case of a vascular 
complication 
 
8. Cath Lab Team 
The number of people in the cath lab along with the different categories of physicians 
performing the procedures differs considerably among the institutions. In GBG, solely 
interventional cardiologists perform the procedures, while in LKPG and NYP a collaboration 
exists between cardiothoracic surgeons and interventional cardiologists. LKPG’s approach 
requires the most staff, followed by NYP, while GBG employs the smallest team. 
In LKPG a thoracic surgeon and two cardiologists (one in training) are present in every case. 
Additionally, a TOE operator and an anaesthesiology team of three are also present. A 
vascular surgeon is on stand-by, as is a perfusionist.  
GBG has no surgical presence in the cath lab but rely on a regular on-call back-up. Neither an 
echocardiographer nor a perfusionist are present, and the anaesthesiology team is 
minimalistic – 1 nurse. 
NYP creates a balance between the abovementioned approaches. 
 
9. Economy 
43 
 
As a result of staff-strategy GBG is a clear winner with regards to cost-effectiveness. Also, 
the valve product they use is less expensive than in NYP and LKPG. In addition, not having 
cardiopulmonary bypass on standby or extensive anaesthesiology equipment further 
contributes to the better economical outcome. 
 
10. Creatinine changes 
It was surprising that there was a decrease in creatinine levels after TAVR as compared to 
before. An administration of contrast was expected to increase the levels. The decrease could 
possibly be explained by that as TAVR treats the aortic stenosis, it also improves the flow of 
blood to the kidneys and therefore improves the kidney function as well. 
Another interesting finding was that the percentage of patients with >25% increase in 
creatinine (definition of contrast induced nephropathy) was not significantly lower in LKPG 
than in GBG (p=0.86), although nearly no contrast is used during the procedure in LKPG. 
Eliminating contrast from the procedure was expected to significantly reduce contrast 
induced nephropathy. The insignificance suggests that it is the contrast administered during 
diagnostics before TAVR that is the main reason for contrast induced nephropathy in the 
setting of TAVR.  
 
3. Outcomes  
1-year Mortality 
The difference in 1-year mortality was an interesting finding. The unexpected discovery of a 
larger proportion of non-high-risk patients in New York compared to Europe further added 
interest to this question. 
The lower overall mortality in New York as compared to Linköping and Gothenburg could be 
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explained by a larger proportion of non-high-risk patients undergoing TAVR. Particularly the 
difference in mortality between Gothenburg and New York in 2016 when 76% of the patients 
in NYP were non-high-risk and only 22% were non-high-risk in GBG. 
The higher 1-year mortality in Gothenburg in 2016 as compared to 2015 could be explained 
by the larger proportion of high-risk patients with more comorbidities undergoing TAVR in 
2016. 
The drop in mortality in New York between 2014 and 2015 could to some extent be 
explained by referring more non-high-risk patients for the procedure (53% vs 72%). 
Also, the overlap in mortality rates and risk scores between Gothenburg and Linköping in 
2014 strengthens the argument that the mortality correlates with the risk score to a certain 
degree, even if the risk scores are not considered to be perfect predictors of mortality in the 
setting of TAVR. 
 
New PPM frequency  
The significantly lower incidence of new PPM with Sapien valves in LKPG compared to 
NYP is also an interesting finding. The incidence was also much lower than what is reported 
in the literature.(17, 46) Procedural changes made by the cardiologists in LKPG could 
explain these findings. An effort is made to eliminate any contact between the tools used 
during TAVR and the conduction system of the heart. The aspects taken into consideration by 
the physicians performing TAVR in LKPG are:  
1. Aiming for a very high valve position – not only the final position but also avoiding a 
low position at ANY point during the procedure.  
2. Visualising the ventricular septum by TEE – this avoids the mechanical destruction of 
conduction tissues. The ventricular septum cannot be seen on fluoroscopy. 
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3. Fewer manipulations are made in proximity to the conduction system – eliminating 
balloon aortic valvuloplasty altogether and eliminating use of catheters. 
All of these factors most likely contribute to lowering the frequency of new PPM after 
TAVR. Since most published data at this time shows a significantly higher frequency of new 
PPM after TAVR as compared to surgical AVR, finding that it is possible to lower the risk to 
<2% or even eliminate the risk for new PPM post TAVR completely, as was achieved in 
LKPG in 2017 is a striking finding. It is a new argument for the advantage of TAVR over 
sAVR adding value to predicting its bright future. 
One of the aspects that could alter the results in a registry to a clinics’ disadvantage is that 
some patients are diagnosed with conditions which are indications for a pacemaker during the 
evaluation for TAVR. Thus, they may have a pacemaker implanted within 30 days after 
TAVR procedure due to the conduction abnormalities discovered before the intervention. 
It is good to recognize the pacemaker indications before TAVR and provide a pacemaker 
accordingly. Otherwise, a patient may be recognized as a pacemaker candidate after TAVR 
and the pacemaker implantation may be falsely interpreted as TAVR complication. In LKPG 
efforts are made to provide the pacemakers to scheduled TAVR recipients before the TAVR 
procedure to avoid this misinterpretation. However, in most cases, waiting time for TAVR is 
shorter (30-60 days) than for elective NPPM implantation and pacemakers are implanted after 
TAVR accordingly. 
 
Furthermore, valve sizing may play a role in the rates of new PPM. Some centres tend to 
oversize the prosthesis in order to prevent perivalvular aortic insufficiency which has been 
identified as a risk factor for reduced survival. Oversizing increases the risk for post TAVR 
AV-block. To oversize or not to oversize – that is the question. Should one prioritize less 
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insufficiency or less AV-block? More research is needed to compare the long-term effects of 
both complications.  
Of note, the data was collected in the beginning of the year with few cases registered in 2018. 
Therefore, it may not show accurate numbers for 2018. 
Stroke 
There were no significant differences in stroke rates between the three institutions. 
Different approaches are utilized to minimize stroke rates in the three institutions, but they 
result in similar outcomes. Perhaps if all clinics combined the best parts of their approaches, 
the stroke rates could be even lower.   
At NYP there is an emphasis on cerebral protection devices, e.g. SENTINEL whereas in 
LKPG the focus is on avoiding manoeuvres in proximity to the thromboembolic areas in the 
aorta through visualising them on TEE and minimizing the use of catheters and passages.  
 
General discussion regarding strengths and weaknesses of the method: 
The strengths of the study were: large number of patients, multi-center study, the registries 
used for data collection are of good quality with few values missing. 
As for weaknesses, there were challenges coming with comparison of different types of 
registries with varying definitions of variables. For example, analysis of vascular 
complications was impossible, and rates of post-dilation were not recorded in the TVT 
registry. 
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Conclusion 
Overall all three centres have low periprocedural, 30-day and 1-year mortality and morbidity 
rates. On average these results appear much better than those reported from high volume 
centres and multicentre studies reported in the literature. 
TAVR results from the three centres are non-inferior and in many aspects superior to 
published surgical AVR series. These findings make a strong argument to extend TAVR 
indications to patients with lower perioperative risks. 
It was also interesting to find out that similar results can be achieved using substantially 
different procedural protocols and perioperative logistics. The centres analysed put different 
priorities in their TAVR refinement programs. The outcomes of these actions achieved the 
desired results. While one centre has succeeded with providing the procedure at much lower 
cost, another one succeeded with excellent survival rates and the third one with impressive 
low rates of complications. This variability paves a way for finding additional enhancements 
in this rapidly expanding technology. Further research is needed to combine the best 
procedural practises for patients undergoing TAVR regardless of centre to develop the 
ultimate TAVR. The final goal being a cost-effective procedure with excellent short and 
long-term outcomes giving the TAVR recipients a long, high quality life seems to be just 
around the corner. 
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Populärvetenskaplig Sammanfattning 
Titel: Förbättring av säkerheten vid aortaklaffbyte – jämförelse av svenska och 
amerikanska tillvägagångssätt 
Aortastenos är en av de vanligaste hjärtsjukdomarna. Det som händer är att en av hjärtats 
klaffar (aortaklaffen) blir stel och öppnas sämre vilket leder till att blod inte kan flöda ut från 
hjärtat till kroppen som vanligt. Prognosen för de drabbade är mycket dålig utan behandling – 
över 50% av patienterna dör inom 2 år om klaffen inte byts ut. Förr var kirurgi det enda sättet 
för att byta ut den sjuka klaffen. Kirurgi är dock ett stort ingrepp med många risker och inte 
alla äldre personer kan genomgå detta. För 10 år sedan tillkom en ny metod som heter TAVR 
som gör att man kan leverera den nya klaffen via kärl, utan kirurgi. Endast ett stick i 
ljumsken behövs. Eftersom metoden är relativt ny utförs den på olika sätt på olika sjukhus 
och komplikationer associerade med den varierar.  
Syftet med den här studien var att jämföra hur ingreppet utförs i Sverige och i USA, vilka 
förbättringar av grundprotokollet som har gjorts och hur de har påverkat 
komplikationsfrekvenser – stroke, nytillkommet behov av pacemaker och mortalitet. 
Detta gjordes genom att data från nationella register samlades in, analyserades och intervjuer 
genomfördes med operatörerna på tre olika sjukhus – Universitetssjukhus i Göteborg, 
Linköping och Presbyterian Hospital i New York. 
Analysen visade att det fanns många metodskillnader i de olika sjukhusen men resultaten var 
i alla fall mycket goda – bättre än de som finns rapporterade för samma metod i litteraturen 
och bättre än för kirurgi. Studien visade att det är möjligt att helt undvika stroke, 
nytillkommet behov av pacemaker och njurskador associerade med proceduren. De olika 
sjukhusen la fokus på olika saker för att förbättra metoden och de lyckades med respektive 
mål. Mortalitetsfrekvensen var lägst i New York, behov av pacemaker var lägst i Linköping 
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och metoden var mest kostnadseffektiv i Göteborg. Den här variabiliteten lägger grunden för 
att hitta det ultimata sättet att utföra TAVR på. Det slutgiltiga målet, vilket är en 
kostnadseffektiv procedur med utmärkta kort- och långtidsresultat verkar vara precis runt 
hörnet. 
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Appendices: 
Additional information about aortic stenosis: 
 
Symptoms of Aortic Stenosis 
The classic triad of symptoms in patients with aortic stenosis is: angina pectoris, syncope and 
shortness of breath. 
Many patients are diagnosed before symptom onset, after a systolic murmur is found on 
physical examination. The diagnosis is then confirmed by echocardiography.  
As the diagnosed patients are followed prospectively, they begin to present with a gradual 
decrease in exercise tolerance, fatigue or exertional dyspnea and ultimately one of the three 
classic symptoms described above.  
Other symptoms include: atrial fibrillation, pulmonary hypertension, systemic venous 
hypertension (late finding), gastrointestinal bleeding (associated with vascular malformations 
and shear stress induced platelet aggregation which resolves after AVR), infective 
endocarditis (younger patients) and transient ischemic attack / stroke or embolization of 
calcium to other organs.  
 
Patients with a bicuspid aortic valve develop symptoms earlier than those with a tricuspid 
valve - at age 50-70 years vs >70 years respectively.(63) Bicuspid aortic valve is often 
associated with dilatation of the ascending aorta that cannot be addressed by TAVR 
nowadays while it can be repaired with AVR. Due to this fact as well as because of the much 
longer valve prosthesis durability required, these patients are better suited for AVR than 
TAVR on most occasions.  
 
Physical Examination  
Auscultation: Ejection systolic murmur (crescendo decrescendo) with radiation to the carotids 
is typical for aortic stenosis.  
Echocardiography: is the widely recognized primary method for evaluating aortic stenosis. It 
is used to define the anatomy of the valve: tricuspid vs bicuspid, the aetiology of stenosis 
(congenital, rheumatic or degenerative calcific), the grade of AS, the severity of valve 
calcification, systolic & diastolic LV function, LV hypertrophy, aortic root dimensions and 
other associated valve disease, for example aortic regurgitation which coexists in 
approximately 75% of patients. This is essential when considering a patient for TAVR vs 
sAVR. In most instances, surgical repair is more suited if multiple valve repairs are needed.  
The transaortic jet velocity, valve area and mean transaortic pressure gradient can be 
measured with Doppler echocardiography. These parameters are used to assess disease 
severity.(63) Also velocity time interval quotient and maximal flow velocity delay are 
helpful.  
 
Special attention must be paid in cases with low LV-function. In these cases, due to low 
stroke volumes many echo-parameters can be falsely negative (max velocity, mean gradient) 
despite a severe grade of stenosis. This condition is named low flow/low gradient severe 
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aortic stenosis. In these cases, the VTI quotient and visual judgement of valve calcification, 
leaflet thickness and mobility are useful. In some cases, special diagnostic tools like stress 
echocardiography or calculation of calcification index from CT can be very helpful. An 
ultimate tool is balloon aortic valvuloplasty (BAV). This is a kind of TAVR rehearsal. 
Eventual clinical improvement after BAV paves way for a patient to be given TAVR that is a 
more long-term solution than BAV. 
 
The European Association of Echocardiography and American Society of Echocardiography 
have published guidelines for the use of echocardiography in potential candidates for TAVR 
since it plays a critical role in the evaluation before the intervention.  
 
ECG: Electrocardiography is generally performed as a part of the initial workup, even though 
it is not indicated for diagnosis of aortic stenosis. Left ventricular hypertrophy is the main 
electrocardiographic change, found in about 85% of patients with severe AS, followed by left 
atrial enlargement - 80%. Other common findings are ST segment depression and T wave 
inversion. Atrial fibrillation is present in 10-15%.(63) p.1474  
ECG may also reveal indications for pacemaker that went unnoticed before the patient was 
considered a TAVR candidate. This is especially essential in patients with symptoms of 
syncope.  
ECG also reveals the pre-TAVR risk factors for a post-TAVR PPM like AV-block I, RBBB, 
bifascicular block or A-fib with low ventricular rate, as well as cases overtreated with drugs 
causing bradyarrhythmia like betablockers. 
 
 
Aspects to be considered by the Heart Team for the decision between SAVR and TAVR in 
patients at increased surgical risk: 
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Figure 16 – Decision-making SAVR vs TAVR. 
Courtesy of European Society of Cardiology 
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